Please login to the form below
COVID-19 and coronavirus
WHO report highlights impact of COVID-19 pandemic on non-communicable diseases
The World Health Organization (WHO) has published a new report highlighting the impact of the COVID-19 pandemic on access to medicines for non-communicable diseases (NCDs). ... The new report, Access to NCD medicines: emergent issues during the COVID-19
Latest news
-
Pfizer/BioNTech’s Omicron-adapted booster approved by FDA for young children
Pfizer and BioNTech’s Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine has been authorised by the US Food and Drug Administration (FDA) for emergency use as a single ... Recent real-world evidence has also shown the bivalent vaccine to be protective
-
Pfizer/BioNTech submit FDA application for Omicron-adapted booster for young children
Pfizer and BioNTech have submitted an application to the US Food and Drug Administration (FDA) for the emergency use of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine ... Vaccine manufacturers have been focused on the development of variant
-
Gilead reports positive real-world evidence for COVID-19 treatment Veklury
Gilead Sciences has reported positive real-world evidence for its COVID-19 treatment, Veklury (remdesivir), demonstrating a reduction in mortality and hospital readmission rates among all patients hospitalised with the virus. ... In a separate analysis,
-
Merck and Ridgeback’s COVID-19 pill fails to prevent infection within households
Lagevrio is already approved to treat certain patients with COVID-19 in several markets. ... The safety profile of Lagevrio was generally consistent with that observed in previously reported clinical studies and post-authorisation experience in the
-
Eiger BioPharmaceuticals reports positive phase 3 results for COVID-19 treatment
US-based Eiger BioPharmaceuticals’ investigational agent, peginterferon lambda (Lambda), significantly reduces the number of clinical events in COVID-19 patients with mild to moderate cases, according to new phase 3 data ... symptom onset, including a
-
NHS urges people yet to receive their COVID-19 booster to come forward
The NHS has urged those who are yet to receive a COVID-19 booster as part of this year’s autumn vaccination programme to book one of the 'hundreds of thousands' ... risk of severe COVID-19 will be able to receive a booster, following updated advice
-
JCVI recommends autumn COVID-19 vaccine booster for those at highest risk
The Joint Committee on Vaccination and Immunisation (JCVI) has advised the UK government that those at a higher risk of severe COVID-19 should be offered a booster vaccination this autumn. ... He also added that the committee will be providing final
-
World Health Organization releases latest set of COVID-19 guidelines
The World Health Organization (WHO) has updated its COVID-19 guidelines on treatments, isolation periods and mask wearing. ... Included in the advice is a strong recommendation for the use of Pfizer’s Paxlovid (nirmatrelvir/ritonavir) in mild or
-
WHO reports new Omicron subvariant cases detected in 29 countries worldwide
Our concern is how transmissible it is.”. Those who have had COVID-19 before are still susceptible to infection, but vaccines are helping to protect against serious illness. ... accounted for over 44% of US COVID-19 cases for the week ending 12 November
-
Valneva reports additional data for COVID-19 booster
Valneva has reported additional data from a small exploratory study of its COVID-19 booster vaccine, VLA2001, for people aged 18 years and older. ... against the spike and other surface proteins, which are thought to help protect against COVID-19.
More from news
Approximately 0 fully matching, plus 651 partially matching documents found.
Latest Intelligence
-
Lessons from a pandemic – holistic strategy in the time of coronavirus
COVID-19 has delivered a scenario where developing the strategy for any brand is a challenge. ... COVID-19 delivered a scenario for which developing the strategy for any brand would have been a challenge.
-
The pandemic preparedness paradox
We must act now. It would be easier to start this work after COVID-19, after we all have our feet under us once again. ... control of COVID-19, the next emergency will draw all attention and sap the collective will.
-
The search for effective drug treatments for COVID-19
a 10-day dosing regimen of remdesivir administered intravenously versus standard of care in patients with moderate manifestations of COVID-19. ... The European Commission has signed a joint procurement agreement for Gilead’s COVID-19 antiviral
-
How will COVID-19 affect uptake of vaccinations against other diseases?
Will COVID-19 help or hinder the quest to increase uptake of other vaccinations? ... Not just for the COVID-19 programmes, but for every other vaccine made these days.
-
The impact of COVID-19 on clinical trials
The novel coronavirus (COVID-19) pandemic has created an unprecedented global health crisis and all industry sectors are working to assess both the impact and the optimal path forward. ... Clinical trials with the following characteristics are especially
More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.
Latest from PMHub
-
WHITE PAPER: Gender inequality—how COVID-19 impacted women
3. Kragholm K et al. Association between male sex and outcomes of Coronavirus Disease 2019 (Covid-19) - a Danish nationwide, register-based study. ... Published 2021. Accessed September 2021. 26. Harapan H et al. Coronavirus disease 2019 (COVID-19): A
-
Black community representation in clinical trials
4]. COVID-19. Coronavirus (COVID-19) has had a devastating impact on countries around the world. ... 6] Office for National Statistics (May, 2020). Coronavirus (COVID-19) related deaths by ethnic group, England and Wales: 2 March 2020 to 10 April 2020.
-
WHITE PAPER: From bench to bedside in one year - how the race for a COVID-19 vaccine will change the future of drug development
Could COVID-19 leave us better prepared for the bigger crisis waiting around the corner? ... The Independent. https://www.independent.co.uk/news/world/americas/coronavirus-vaccine-phase-3-covid-fda-cure-a9704111.html. Published 2020. Accessed May 26, 2021
-
COVID-proof: How Teams are Creating Launch Intensity thru Adversity
Impact of COVID-19 on Pharmaceuticals Market Size, Share &Industry Analysis. ... COVID-19: UK industry focus – Where next for pharma and life sciences?
-
Unpacking rare diseases in the first edition of Delta magazine
A patient’s account of living with a rare disease in the COVID-19 pandemic. ... The lasting implications of COVID-19 on the life science industry.
-
Mistrust in medical research: a patient perspective
The Thalidomide Society has said that comparisons between thalidomide and the COVID-19 vaccine are “insulting”. ... The Royal Society of Medicine has been running a series of COVID-19 webinars.
-
How will the events and exhibitions industry change post-Coronavirus?
The Covid-19 global pandemic has permanently changed the events and exhibitions industry. ... However, the impact of Covid-19 will have changed how we work forever.
-
Will COVID-19 necessitate a change in thinking around clinical trials?
The global outbreak of coronavirus (COVID-19) and current misinformation infiltrating our consciousness on social media has been a challenge to get our heads around, but it’s undeniable that ... This blog was first published here:
-
Could coronavirus turn us all into online gamers?
As businesses gauge the potential impact of coronavirus (COVID-19), with a sense of fear and pessimism causing a dampening of economic activity and suspension of the stock market, the healthcare ... We’ve put our actively considerate heads together and
-
Keeping calm and carrying on: COVID-19 and approaches to CME/CPD during a viral outbreak
Celeste Kolanko, Managing Director, Liberum OPEN Health. As the incidences of the Coronavirus COVID-19 are growing, it’s a good time to reflect on its effects on CME/CPD to
More from PMHub
Approximately 0 fully matching, plus 13 partially matching documents found.
Subscribe to our email news alerts
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Senior Medical Writer
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- MHRA to introduce new UK clinical trials framework
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- 2023 PM Society Awards – winners announced
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- Pfizer and Astellas’ Xtandi shows promise in phase 3 prostate cancer study
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- WHO report highlights impact of COVID-19 pandemic on non-communicable diseases
- Critical success factors and the increasing value of rare disease clinical trials
- Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- Biogen and Eisai’s Alzheimer’s drug to be covered by US Veterans Health Administration
- VR/AR Applications for Training and Healthcare
PMHub
CHASE
We are a leading provider of outsourced commercial, medical and recruitment services to UK pharmaceutical, biotech and healthcare companies....
Latest intelligence
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
